Notably, a recent phase 2 clinical trial (NCT03939234) explored a PD-L1/PD-L2 peptide vaccine in chronic lymphocytic leukemia, demonstrating the potential of PD-L2 targeting strategies even in the absence of established inhibitors [67]. The gene discussed is PDCD1LG2; the disease is B-cell chronic lymphocytic leukemia.